ID: ALA2113434

Max Phase: Preclinical

Molecular Formula: C11H14N6O5

Molecular Weight: 310.27

Molecule Type: Small molecule

Representations

Canonical SMILES:  CONC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C11H14N6O5/c1-21-16-10(20)7-5(18)6(19)11(22-7)17-3-15-4-8(12)13-2-14-9(4)17/h2-3,5-7,11,18-19H,1H3,(H,16,20)(H2,12,13,14)/t5-,6+,7-,11+/m0/s1

Standard InChI Key:  FCAHXBLMILKKQK-QMWPFBOUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 310.27

Molecular Weight (Monoisotopic): 310.1026

AlogP: -2.29

#Rotatable Bonds: 3

Polar Surface Area: 157.64

Molecular Species: ACID

HBA: 10

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 11

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.47

CX Basic pKa: 4.94

CX LogP: -2.96

CX LogD: -3.15

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.46

Np Likeness Score: 0.60

References

1. de Zwart M, Kourounakis A, Kooijman H, Spek AL, Link R, von Frijtag Drabbe Künzel JK, IJzerman AP..  (1999)  5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.,  42  (8): [PMID:10212124] [10.1021/jm9804984]

2. Umino T, Yoshioka K, Saitoh Y, Minakawa N, Nakata H, Matsuda A..  (2001)  Nucleosides and nucleotides. 200. Reinvestigation of 5'-N-ethylcarboxamidoadenosine derivatives: structure-activity relationships for P(3) purinoceptor-like proteins.,  44  (2): [PMID:11170630] [10.1021/jm000150k]

3. Prasad RN, Bariana DS, Fung A, Savic M, Tietje K, Stein HH, Brondyk H, Egan RS..  (1980)  Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides.,  23  (3): [PMID:7365748] [10.1021/jm00177a021]

Source

Source(1):

• Scientific Literature